Fabry's disease (description of a clinical case)

The article describes a clinical case of Fabry’s disease – orphan hereditary X-linked disease, characterized by the accumulation of sphingolipids in various organs and the development of their dysfunction. This disease can occur in the practice of doctors of various specialties, and the patient's prognosis depends on early diagnosis and enzyme replacement therapy. 
The purpose of the article is to describe a clinical case of cardiological manifestation of Fabry's disease in a woman. The article discusses the pathogenesis of Fabry's disease, the symptoms of the disease, the management and criteria for treatment effectiveness.

1. Pande S., Varzideh F., Gambardella J. et al. Fabry disease cardiomyopathy: A state-of-the-art review. Prog Cardiovasc Dis. 2025;92:43–65.

2. Amodio F., Caiazza M., Monda E. et al. An Overview of Molecular Mechanisms in Fabry Disease. Biomolecules. 2022;12:1460.

3. Kurdi H., Lavalle L., Moon J. C. C., Hughes D. Inflammation in Fabry disease: stages, molecular pathways, and therapeutic implications. Front. Cardiovasc. Med. 2024;11:1420067.

4. Izhar R., Borriello M., La Russa A. et al. Fabry Disease in Women: Genetic Basis, Available Biomarkers, and Clinical Manifestations. Genes. 2024;15:37.

5. Faro D. C., Losi V., Rodolico M. S. et al. Sex Differences in Anderson-Fabry Cardiomyopathy: Clinical, Genetic, and Imaging Analysis in Women. Genes (Basel). 2023;14(9):1804. https://doi.org/10.3390/genes14091804.

6. Pieroni M., Namdar M., Olivotto I., Desnick R. J. Anderson-Fabry disease management: role of the cardiologist. Eur Heart J. 2024;45(16):1395–1409. https://doi.org/10.1093/eurheartj/ehae148.

7. Lenders M., Menke E. R., Brand E. Progress and Challenges in the Treatment of Fabry Disease. BioDrugs. 2025;39(4):517–535. https://doi.org/10.1007/s40259-025-00723-3.

8. Tognola C., Ruzzenenti G., Maliberti A. et al. Anderson-Fabri Disease: An Overview of Current Diagnosis, Arrhythmic Risk Stratification and Therapeutic Strategies. Diagnostics. 2025;15(139):1–16. https://doi.org/10.3390/diagnostics15029139.

9. Morrone A., Cavicchi C., Bardelli T. et al. Fabry disease: molecular studies in Italian patients and X inactivation analysis in manifesting carriers. J Med Genet. 2003;40(8):e103.

10. Bouwman M. G., Rombach S. M., Linthorst G. E. et al. Early cerebral manifestations in a young female with Fabry disease with skewed X-inactivation. Clin Genet. 2011;80(5):500–2.

11. Maier E. M., Osterrieder S., Whybra C. et al. Disease manifestations and X inactivation in heterozygous females with Fabry disease. Acta Paediatr Suppl. 2006;95(451):30–8.

12. Di Risi T., Vinciguerra R., Cuomo M. et al. DNA methylation impact on Fabry disease. Clin Epigenetics. 2021;13(1):24.

13. Hossain M. A., Yanagisawa H., Miyajima T. et al. The severe clinical phenotype for a heterozygous Fabry female patient correlates to the methylation of nonmutated allele associated with chromosome 10q26 deletion syndrome. Mol Genet Metab. 2017;120(3):173–179. https://doi.org/10.1016/j.ymgme.2017.01.002.

14. Moiseev A. S., Tao E. A., Bulanov N. M. et al. Features of clinical phenotypes of Fabry’s disease in adult men and women. Klin Pharmacol ter. 2025;34(2):31–36. (In Russ.).

15. Linhart A., Germain D. P., Olivotto I. et al. An expert consensus document on the management of cardiovascular manifestations of Fabry disease. Eur J Heart Fail. 2020;22(7):1076–1096. https://doi.org/10.1002/ejhf.1960.

16. Pieroni M., Moon J. C., Arbustini E. et al. Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2021;77(7):922–936. https://doi.org/10.1016/j.jacc.2020.12.024.

17. Jovanovic A., Miller-Hodges E., Castriota F. et al. Clinical Efficacy and RealWorld Effectiveness of Fabry Disease Treatments: A Systematic Literature Review. J Clin Med. 2025;14(14):5131. https://doi.org/10.3390/jcm14145131.

18. Holida M., Linhart A., Pisani A. et al. A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies. J Inherit Metab Dis. 2025;48(1):e12795. https://doi.org/10.1002/jimd.12795.

19. Germain D. P., Linhart A. Pegunigalsidase alfa: a novel, pegylated recombinant alpha-galactosidase enzyme for the treatment of Fabry disease. Front Genet. 2024;15:1395287. https://doi.org/10.3389/fgene.2024.1395287.

20. British Inherited Metabolic Diseases Group 2025 Guidelines for the treatment of Fabry Disease. URL: https://bimdg.org.uk/wp-content/uploads/2025/07/2025.05.30.Fabry-Clinical-Guidance.pdf(accessed: 25.06.26).